SCHEMBL2894033

SCHEMBL2894033

O=C(NCCO)Nc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 5/20 0.64
KDM4E B2RXH2 1/20 0.64
HTT P42858 2/20 0.62
ALDH1A1 P00352 1/20 0.62
SMN1; SMN2 Q16637 4/20 0.61
TP53 P04637 2/20 0.61
TSHR P16473 1/20 0.61
EPHX2 P34913 1/20 0.61
CDK9 P50750 1/20 0.61
CLK4 Q9HAZ1 1/20 0.61
HDAC1 Q13547 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
MEN1 O00255 2/20 0.57
POLB P06746 2/20 0.57
KMT2A Q03164 2/20 0.57
LMNA P02545 1/20 0.57
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
CNR1 P21554 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11051077 0.90 EPHX1 (0.70) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL21583073 0.90 KDM4E (0.60) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL3065011 0.89 EPHX1 (0.70) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL12661777 0.87 EPHX1 (0.71) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL2446111 0.86 EPHX1 (0.77) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL15741133 0.85 EPHX1 (0.73) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL3513673 0.84 EPHX1 (0.64) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL325607 0.84 EPHX1 (0.64) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL9547553 0.84 EPHX1 (0.83) EPHX1KDM4EHTTALDH1A1SMN1; SMN2
SCHEMBL19420655 0.84 EPHX1 (0.83) EPHX1KDM4EHTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1511730-B8 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2009-04-08 EP claimed
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases FLOERSHEIMER ANDREAS 2006-06-15 US claimed
EP-1511730-A2 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-09 EP claimed
WO-2003099771-A2 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-12-04 WO claimed
US-12351542-B2 Spacered urea (meth)acrylates EVONIK OPERATIONS GMBH (DE) 2025-07-08 US disclosed
US-12338202-B2 One pot synthesis of urea (meth)acrylates EVONIK OPERATIONS GMBH (DE) 2025-06-24 US disclosed
EP-4148041-B1 SPACERED UREA (METH)ACRYLATES EVONIK OPERATIONS GMBH (DE) 2023-11-01 EP disclosed
EP-4148040-B1 ONE POT SYNTHESIS OF UREA (METH)ACRYLATES EVONIK OPERATIONS GMBH (DE) 2023-11-01 EP disclosed
EP-4148040-B1 ONE POT SYNTHESIS OF UREA (METH)ACRYLATES EVONIK OPERATIONS GMBH (DE) 2023-11-01 EP disclosed
US-20230101100-A1 One Pot Synthesis of Urea (Meth)Acrylates EVONIK OPERATIONS GMBH (DE) 2023-03-30 US disclosed
US-20230088931-A1 Spacered Urea (Meth)Acrylates EVONIK OPERATIONS GMBH (DE) 2023-03-23 US disclosed
EP-4148040-A1 ONE POT SYNTHESIS OF UREA (METH)ACRYLATES Evonik Operations GmbH (DE) 2023-03-15 EP disclosed
CN-1301699-A New direct chain or cyclic urea, its preparing method and medicinal composition containing them ADIR (FR) 2001-07-04 CN disclosed
EP-0232623-B1 1-CARBACEPHALOSPORIN ANTIBIOTICS ELI LILLY AND COMPANY (US) 1993-03-17 EP disclosed
US-4918091-A HYPERGLYCEMIC, ANTILIPEMIC AGENTS BEECHAM GROUP P.L.C. (GB) 1990-04-17 US disclosed
US-4892942-A 1-CARBA (DETHIA)CEPHALOSPORINS ELI LILLY AND COMPANY (US) 1990-01-09 US disclosed
EP-0295828-A1 Novel compounds BEECHAM GROUP PLC (GB) 1988-12-21 EP disclosed
US-4791106-A 1-Carbacephalosporin antibiotics ELI LILLY AND COMPANY (US) 1988-12-13 US disclosed
EP-0232623-A1 1-Carbacephalosporin antibiotics ELI LILLY AND COMPANY (US) 1987-08-19 EP disclosed
US-4435567-A REACTING AN AMINE WITH AN N-CARBAMOYL BENZOIC ACID SULFIMIDE CHINOIN GYOGYSZER ES VESGYESZETI TERMEKEK GYARA R. T. (HU) 1984-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351542-B2 Spacered urea (meth)acrylates METTL14, METTL3, FUS EPHX1 3389/4885KDM4E 821/4885HTT 323/4885
US-12338202-B2 One pot synthesis of urea (meth)acrylates ADH1A, ADH1C, METTL14 EPHX1 2807/4885KDM4E 1350/4885HTT 62/4885
US-20230101100-A1 One Pot Synthesis of Urea (Meth)Acrylates ADH1A, ADH1C, METTL14 EPHX1 2807/4885KDM4E 1350/4885HTT 62/4885
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases UCK2, PRKDC, PRKACA EPHX1 2991/4885KDM4E 1003/4885HTT 2115/4885
US-20230088931-A1 Spacered Urea (Meth)Acrylates METTL14, METTL3, FUS EPHX1 3389/4885KDM4E 821/4885HTT 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.